Javascript must be enabled to continue!
P175 TRANSLATION OF MINIMALLY INVASIVE ESOPHAGECTOMY FROM RANDOMIZED CONTROLLED TRIAL SETTING (TIME) TO NATIONAL PRACTICE (DUCA) IN NETHERLANDS
View through CrossRef
Abstract
Aims
The TIME trial showed reduced pulmonary complications from minimally invasive esophagectomy (MIE) over an open approach, and led to widespread adoption of MIE in the Netherlands. The aim of this study was to compare clinical outcomes from minimally invasive esophagectomy in the DUCA (national dataset) and the TIME trial (RCT) for transthoracic esophagectomy1.
Methods
Original patient data from the TIME trial1 was extracted along-with data from the Dutch National Cancer Audit (DUCA) (2011-2017). Initially univariate analysis was used to compare patient and tumor demographics and clinical and pathological outcomes from patients receiving MIE in the TIME trial and in the DUCA-dataset. Secondly multivariate analysis, with adjustment patient and tumor factors, was performed for the effect of MIE vs. Open esophagectomy on clinical outcomes in both datasets. Thirdly the datasets were combined and multivariate analysis, was performed for the effect of patient inclusion in TIME trial or DUCA-dataset.
Results
115 patients from TIME (59 MIE vs. 56 open) and 4605 patients from the DUCA-dataset (2652 MIE vs. 1953 open) were included. Univariate analysis showed, in TIME trial, MIE reduced postoperative complications and length of hospital stay. However in the DUCA-dataset, MIE increased postoperative complications, re-intervention rate and length of hospital stay, however pathological benefits included increased proportion of R0 margin and lymph nodes harvested.
Multivariate analysis confirmed the TIME data showed MIE reduced postoperative complications (OR=0.38, 95%CI 0.16–0.90). In the DUCA-dataset, MIE was associated with increased postoperative complications (OR=1.37, 95%CI 1.20–1.55), re-intervention (OR=1.84, 95%CI 1.57–2.14), and length of hospital stay (Coeff=1.57, 95%CI 0.06–3.08). Pathological benefits to MIE in the DUCA-dataset included a reduction in proportion of R1 margin, and increased lymph node harvest.
Multivariate analysis of the combined dataset, showed inclusion in the TIME trial was associated with a reduction in postoperative complications (OR=0.23, 95%CI 0.15–0.36) and reoperation rate (OR=0.34, 95%CI 0.17–0.66).
Conclusions
MIE when adopted nationally outside the TIME-trial, was associated with an increase in postoperative complications and reoperation rate, which may reflect surgeons on a national level going through their proficiency-gain curve in the technique and outside of expert MIE centers.
Title: P175 TRANSLATION OF MINIMALLY INVASIVE ESOPHAGECTOMY FROM RANDOMIZED CONTROLLED TRIAL SETTING (TIME) TO NATIONAL PRACTICE (DUCA) IN NETHERLANDS
Description:
Abstract
Aims
The TIME trial showed reduced pulmonary complications from minimally invasive esophagectomy (MIE) over an open approach, and led to widespread adoption of MIE in the Netherlands.
The aim of this study was to compare clinical outcomes from minimally invasive esophagectomy in the DUCA (national dataset) and the TIME trial (RCT) for transthoracic esophagectomy1.
Methods
Original patient data from the TIME trial1 was extracted along-with data from the Dutch National Cancer Audit (DUCA) (2011-2017).
Initially univariate analysis was used to compare patient and tumor demographics and clinical and pathological outcomes from patients receiving MIE in the TIME trial and in the DUCA-dataset.
Secondly multivariate analysis, with adjustment patient and tumor factors, was performed for the effect of MIE vs.
Open esophagectomy on clinical outcomes in both datasets.
Thirdly the datasets were combined and multivariate analysis, was performed for the effect of patient inclusion in TIME trial or DUCA-dataset.
Results
115 patients from TIME (59 MIE vs.
56 open) and 4605 patients from the DUCA-dataset (2652 MIE vs.
1953 open) were included.
Univariate analysis showed, in TIME trial, MIE reduced postoperative complications and length of hospital stay.
However in the DUCA-dataset, MIE increased postoperative complications, re-intervention rate and length of hospital stay, however pathological benefits included increased proportion of R0 margin and lymph nodes harvested.
Multivariate analysis confirmed the TIME data showed MIE reduced postoperative complications (OR=0.
38, 95%CI 0.
16–0.
90).
In the DUCA-dataset, MIE was associated with increased postoperative complications (OR=1.
37, 95%CI 1.
20–1.
55), re-intervention (OR=1.
84, 95%CI 1.
57–2.
14), and length of hospital stay (Coeff=1.
57, 95%CI 0.
06–3.
08).
Pathological benefits to MIE in the DUCA-dataset included a reduction in proportion of R1 margin, and increased lymph node harvest.
Multivariate analysis of the combined dataset, showed inclusion in the TIME trial was associated with a reduction in postoperative complications (OR=0.
23, 95%CI 0.
15–0.
36) and reoperation rate (OR=0.
34, 95%CI 0.
17–0.
66).
Conclusions
MIE when adopted nationally outside the TIME-trial, was associated with an increase in postoperative complications and reoperation rate, which may reflect surgeons on a national level going through their proficiency-gain curve in the technique and outside of expert MIE centers.
Related Results
Tổng quan về cắt thực quản hiện đại
Tổng quan về cắt thực quản hiện đại
Tóm tắt
Mục tiêu: Trình bày tổng quan về cắt thực quản thời hiện đại.
Năm 1913, Franz John Torek (1861-1938) người Đức làm việc tại bệnh viện Lenox Hill, Newyork City, là người ...
063. ROBOTIC ASSISTED MIMINALLY INVASIVE IVOR-LEWIS ESOPHAGECTOMY VERSUS CONVENTIONAL MINIMALLY INVASIVE IVOR-LEWIS ESOPHAGECTOMY
063. ROBOTIC ASSISTED MIMINALLY INVASIVE IVOR-LEWIS ESOPHAGECTOMY VERSUS CONVENTIONAL MINIMALLY INVASIVE IVOR-LEWIS ESOPHAGECTOMY
Abstract
Background
Minimally invasive technique for esophagectomy has emerged as the standard of care for resectable esophageal...
596. MINIMALLY INVASIVE ESOPHAGECTOMY FOR ESOPHAGEAL AND GASTRO-ESOPHAGEAL JUNCTION TUMORS. A SINGLE CENTER EXPERIENCE
596. MINIMALLY INVASIVE ESOPHAGECTOMY FOR ESOPHAGEAL AND GASTRO-ESOPHAGEAL JUNCTION TUMORS. A SINGLE CENTER EXPERIENCE
Abstract
Esophagectomy carries high rates of post-operative morbidity and mortality. Minimally invasive esophagectomy was introduced more than 20 years ago offering ...
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Abstract
Introduction
Although the efficacy of PD-L1 blockade has been evaluated in analyses that combine pharmacologically distinct antibodies, the specific efficacy and safety of...
Prognostic factors influencing morbidity and mortality in esophageal carcinoma
Prognostic factors influencing morbidity and mortality in esophageal carcinoma
PURPOSE: In 1980, operative mortality for esophageal resection was 29%. Over the last 15 years, technical and critical care improvements contributed to the reduction of postoperati...
Robotic resection for esophageal cancer
Robotic resection for esophageal cancer
Summary
Background
In the surgical treatment of esophageal cancer, complete tumor resection is the most important factor and determines long-term su...
OUTCOMES OF IVOR-LEWIS AND MINIMAL INVASIVE MCKEOWN ESOPHAGECTOMY FOR
LOWER AND MIDDLE ESOPHAGEAL CANCER.
OUTCOMES OF IVOR-LEWIS AND MINIMAL INVASIVE MCKEOWN ESOPHAGECTOMY FOR
LOWER AND MIDDLE ESOPHAGEAL CANCER.
Background: Ivor-Lewis esophagectomy and Mckewon esophagectomy are used to treat esophageal cancer, and minimally
invasive technique is increasingly adopted to lower morbidities an...
587. ROLE OF THORACOSCOPIC HAND-SEWN ESOPHAGO-GASTRIC ANASTOMOSIS IN 2-STAGE TOTALLY MINIMALLY INVASIVE ESOPHAGECTOMY. REPORT OF 200 CONSECUTIVE CASES
587. ROLE OF THORACOSCOPIC HAND-SEWN ESOPHAGO-GASTRIC ANASTOMOSIS IN 2-STAGE TOTALLY MINIMALLY INVASIVE ESOPHAGECTOMY. REPORT OF 200 CONSECUTIVE CASES
Abstract
Esophagectomy is the mainstay of treatment of esophageal and gastro-esophageal junction cancer. Minimally invasive esophagectomy has been introduced in the ...

